Two strains of lactobacillus reuteri with high efficiency of degrading nucleosides and application thereof
By efficiently degrading nucleosides and uric acid using Lactobacillus reuteri W6-12 and W6-5, the adverse reaction problems of existing drugs are solved, providing a safe and effective treatment for hyperuricemia, which is suitable for food, medicine and health products.
CN122278690APending Publication Date: 2026-06-26GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY +2
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY
- Filing Date
- 2026-03-24
- Publication Date
- 2026-06-26
Smart Images
Figure CN122278690A_ABST
Abstract
This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.
Need to check novelty before this filing date? Find Prior Art